In this article, we will discuss Idecabtagene Vicleucel (Mechanism of Action). So, let’s get started.
Mechanism of Action
Idecabtagene vicleucel is a chimeric antigen receptor (CAR)-positive T cell therapy targeting B-cell maturation antigen
(BCMA), which is expressed on the surface of normal and malignant plasma cells. The CAR construct includes an anti-BCMA scFv-targeting domain for antigen specificity, a transmembrane domain, a CD3-zeta T cell activation domain, and a 4-1BB costimulatory domain. Antigen-specific activation of Idecabtagene vicleucel results in CAR-positive T cell proliferation, cytokine secretion, and subsequent cytolytic killing of BCMA-expressing cells.
Following Idecabtagene vicleucel infusion, pharmacodynamic responses of CAR activation and anti-tumor efficacy were
evaluated. Peak elevation of plasma cytokines, chemokines, and soluble immune mediators occurred within 14 days of Idecabtagene vicleucel infusion and returned to baseline levels within one month.
Rapid decreases in tumor markers associated with clinical response, including serum levels of soluble BCMA, and bone marrow CD138+ cells, as well as minimal residual disease (MRD) negative responses, were observed within the first month following Idecabtagene vicleucel infusion.